Skip to main content

2 Result(s)

within J. P. Droz Remove this filter Cancer Research Remove this filter Pharmacology/Toxicology Remove this filter

and

  1. No Access

    Article

    Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer

     Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor m...

    C. Maulard, J. P. Droz, D. Jessueld, M. Housset… in Cancer Chemotherapy and Pharmacology (1995)

  2. No Access

    Article

    Phase I–II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer

    Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor mo...

    C. Maulard, P. Richaud, J. P. Droz, D. Jessueld… in Cancer Chemotherapy and Pharmacology (1995)